跳至主要内容
临床试验/EUCTR2022-002891-35-FR
EUCTR2022-002891-35-FR进行中(未招募)1 期

REVErsing airway Remodelling with Tezepelumab (REVERT): a protocol for a double-blind randomized controlled trial for patients with asthma - REVERT

niversity Hospital of Montpellier0 个研究点目标入组 90 人开始时间: 2024年4月9日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Admitted to screening visit:
  • Minimum age: 18
  • Maximum age: 85
  • Able to perform an inspiratory and expiratory thoracic computed tomography (CT) scan, plus a nasal CT
  • Physician-diagnosed asthma according to GINA criteria
  • Disease with clinical impact: at least 1 severe or 2 moderate exacerbations† in the previous 12 months despite treatment according to the best standards of care
  • Maximal inhaled therapy comprising high dose ICS and at least a second controller according to GINA
  • Based on results of screening visit and run-in:
  • Post-bronchodilator forced expiratory volume in 1 second (FEV1) predicted values must be at 25-90%
  • Asthma Control Questionnaire 6 (ACQ6) > 1.5
  • Oral corticosteroid maintenance therapy (if used) is ?7.5 mg/day
  • In stable condition for the 4-week run-in period
  • On CT scan, the average percentage wall area index at the B1 and B8 bronchi (generation 3) is >65%
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • CT abnormalities evocative of any respiratory condition other than asthma‡
  • Treatment regimen discordant with best practices
  • Pulmonary disease other than asthma‡ requiring treatment during the previous 12 months
  • A smoking history of >20 pack years
  • Biological therapy§ during the past 3 months
  • Absence of signed consent
  • Non-beneficiary of the French social security, single-payer health insurance system
  • Presence of any condition (physical, psychological or other) that might, in the investigator’s opinion, hinder study performance††
  • The patient is unavailable or unwilling to participate in future visits
  • Potential interference from other studies‡‡
  • Protected populations according to the French public health code§§
  • Male or female patients seeking to conceive a child

研究者

发起方
niversity Hospital of Montpellier

相似试验